## Theresa M Winhusen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4006457/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Internet-Delivered Treatment for Substance Abuse: A Multisite Randomized Controlled Trial. American Journal of Psychiatry, 2014, 171, 683-690.	7.2	203
2	Bringing Buprenorphine-Naloxone Detoxification to Community Treatment Providers: The NIDA Clinical Trials Network Field Experience. American Journal on Addictions, 2004, 13, S42-S66.	1.4	130
3	Randomized Controlled Trial of Osmotic-Release Methylphenidate With Cognitive-Behavioral Therapy in Adolescents With Attention-Deficit/Hyperactivity Disorder and Substance Use Disorders. Journal of the American Academy of Child and Adolescent Psychiatry, 2011, 50, 903-914.	0.5	102
4	A placebo-controlled screening trial of tiagabine, sertraline and donepezil as cocaine dependence treatments. Addiction, 2005, 100, 68-77.	3.3	85
5	Motivational enhancement therapy to improve treatment utilization and outcome in pregnant substance users. Journal of Substance Abuse Treatment, 2008, 35, 161-173.	2.8	82
6	Medication assisted treatment discontinuation in pregnant and postpartum women with opioid use disorder. Drug and Alcohol Dependence, 2015, 149, 225-231.	3.2	81
7	Impact of Attention-Deficit/Hyperactivity Disorder (ADHD) Treatment on Smoking Cessation Intervention in ADHD Smokers. Journal of Clinical Psychiatry, 2010, 71, 1680-1688.	2.2	78
8	A medication screening trial evaluation of reserpine, gabapentin and lamotrigine pharmacotherapy of cocaine dependence. Addiction, 2005, 100, 58-67.	3.3	61
9	Predictors of outcome for short-term medically supervised opioid withdrawal during a randomized, multicenter trial of buprenorphine–naloxone and clonidine in the NIDA clinical trials network drug and alcohol dependence. Drug and Alcohol Dependence, 2009, 99, 28-36.	3.2	59
10	Risk factors for opioid overdose and awareness of overdose risk among veterans prescribed chronic opioids for addiction or pain. Journal of Addictive Diseases, 2016, 35, 42-51.	1.3	55
11	Design and methodological considerations of an effectiveness trial of a computer-assisted intervention: An example from the NIDA Clinical Trials Network. Contemporary Clinical Trials, 2012, 33, 386-395.	1.8	50
12	The Opioid-overdose Reduction Continuum of Care Approach (ORCCA): Evidence-based practices in the HEALing Communities Study. Drug and Alcohol Dependence, 2020, 217, 108325.	3.2	50
13	The HEALing (Helping to End Addiction Long-term SM) Communities Study: Protocol for a cluster randomized trial at the community level to reduce opioid overdose deaths through implementation of an integrated set of evidence-based practices. Drug and Alcohol Dependence, 2020, 217, 108335.	3.2	50
14	A Randomized Trial of Concurrent Smoking-Cessation and Substance Use Disorder Treatment in Stimulant-Dependent Smokers. Journal of Clinical Psychiatry, 2014, 75, 336-343.	2.2	50
15	The HPA Axis in Cocaine Use. Journal of Addictive Diseases, 2001, 20, 105-119.	1.3	49
16	Impulsivity is associated with treatment non-completion in cocaine- and methamphetamine-dependent patients but differs in nature as a function of stimulant-dependence diagnosis. Journal of Substance Abuse Treatment, 2013, 44, 541-547.	2.8	48
17	A randomized pilot clinical trial to evaluate the efficacy of Community Reinforcement and Family Training for Treatment Retention (CRAFT-T) for improving outcomes for patients completing opioid detoxification. Drug and Alcohol Dependence, 2014, 138, 240-243.	3.2	47
18	Multisite, Randomized, Double-Blind, Placebo-Controlled Pilot Clinical Trial to Evaluate the Efficacy of Buspirone as a Relapse-Prevention Treatment for Cocaine Dependence. Journal of Clinical Psychiatry, 2014, 75, 757-764	2.2	47

#	Article	IF	CITATIONS
19	A double-blind, placebo-controlled trial of tiagabine for the treatment of cocaine dependence. Drug and Alcohol Dependence, 2007, 91, 141-148.	3.2	46
20	An Open-Label Pilot Study of Methylphenidate in the Treatment of Cocaine Dependent Patients with Adult Attention Deficit/ Hyperactivity Disorder. Journal of Addictive Diseases, 2004, 23, 77-92.	1.3	44
21	Methylphenidate and cocaine: A placebo-controlled drug interaction study. Pharmacology Biochemistry and Behavior, 2006, 85, 29-38.	2.9	43
22	Medical complications associated with substance use disorders in patients with type 2 diabetes and hypertension: electronic health record findings. Addiction, 2019, 114, 1462-1470.	3.3	43
23	Achieving Cannabis Cessation — Evaluating N-acetylcysteine Treatment (ACCENT): Design and implementation of a multi-site, randomized controlled study in the National Institute on Drug Abuse Clinical Trials Network. Contemporary Clinical Trials, 2014, 39, 211-223.	1.8	42
24	Predictors of treatment response in adolescents with comorbid substance use disorder and attention-deficit/hyperactivity disorder. Journal of Substance Abuse Treatment, 2013, 44, 224-230.	2.8	41
25	Regular cannabis use, with and without tobacco co-use, is associated with respiratory disease. Drug and Alcohol Dependence, 2019, 204, 107557.	3.2	40
26	Subjective Effects, Misuse, and Adverse Effects of Osmotic-Release Methylphenidate Treatment in Adolescent Substance Abusers with Attention-Deficit/Hyperactivity Disorder. Journal of Child and Adolescent Psychopharmacology, 2011, 21, 455-463.	1.3	39
27	Gender Research in the National Institute on Drug Abuse National Treatment Clinical Trials Network: A Summary of Findings. American Journal of Drug and Alcohol Abuse, 2011, 37, 301-312.	2.1	37
28	Total antioxidant capacity is significantly lower in cocaineâ€dependent and methamphetamineâ€dependent patients relative to normal controls: results from a preliminary study. Human Psychopharmacology, 2014, 29, 537-543.	1.5	37
29	A Multisite, Double-blind, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Vigabatrin for Treating Cocaine Dependence. JAMA Psychiatry, 2013, 70, 630.	11.0	36
30	Achieving smoking abstinence is associated with decreased cocaine use in cocaine-dependent patients receiving smoking-cessation treatment. Drug and Alcohol Dependence, 2014, 134, 391-395.	3.2	35
31	A double-blind, placebo-controlled trial of reserpine for the treatment of cocaine dependence. Drug and Alcohol Dependence, 2007, 91, 205-212.	3.2	32
32	Major depression and treatment response in adolescents with ADHD and substance use disorder. Drug and Alcohol Dependence, 2012, 120, 214-219.	3.2	31
33	Measuring outcome in cocaine clinical trials: a comparison of sweat patches with urine toxicology and participant self-report. Addiction, 2003, 98, 317-324.	3.3	29
34	Frontal systems deficits in stimulant-dependent patients: Evidence of pre-illness dysfunction and relationship to treatment response. Drug and Alcohol Dependence, 2013, 127, 94-100.	3.2	28
35	Attention-Deficit/Hyperactivity Disorder Subtypes in Adolescents with Comorbid Substance-Use Disorder. American Journal of Drug and Alcohol Abuse, 2012, 38, 93-100.	2.1	26
36	Using buprenorphine short-term taper to facilitate early treatment engagement. Journal of Substance Abuse Treatment, 2007, 32, 349-356.	2.8	25

#	Article	IF	CITATIONS
37	Cocaine Rapid Efficacy Screening Trials (CREST): lessons learned. Addiction, 2005, 100, 102-110.	3.3	24
38	Multisite effectiveness trials of treatments for substance abuse and co-occurring problems: Have we chosen the best designs?. Journal of Substance Abuse Treatment, 2010, 38, S97-S112.	2.8	24
39	External pressure, motivation, and treatment outcome among pregnant substance-using women. Drug and Alcohol Dependence, 2010, 107, 149-153.	3.2	23
40	Cigarette and cannabis use trajectories among adolescents in treatment for attention-deficit/hyperactivity disorder and substance use disorders. Drug and Alcohol Dependence, 2011, 117, 242-247.	3.2	23
41	Decision-making processes as predictors of relapse and subsequent use in stimulant-dependent patients. American Journal of Drug and Alcohol Abuse, 2016, 42, 88-97.	2.1	23
42	OROS-methylphenidate or placebo for adult smokers with attention deficit hyperactivity disorder: Racial/ethnic differencesâ~†. Drug and Alcohol Dependence, 2010, 110, 156-159.	3.2	22
43	The association between regular cannabis use, with and without tobacco co-use, and adverse cardiovascular outcomes: cannabis may have a greater impact in non-tobacco smokers. American Journal of Drug and Alcohol Abuse, 2020, 46, 454-461.	2.1	22
44	Pharmacological Management of Opioid Use Disorder in Pregnant Women. CNS Drugs, 2015, 29, 625-636.	5.9	21
45	Incentives for retention of pregnant substance users: A secondary analysis. Journal of Substance Abuse Treatment, 2010, 38, 90-95.	2.8	20
46	Divergence by ADHD Subtype in Smoking Cessation Response to OROS-Methylphenidate. Nicotine and Tobacco Research, 2011, 13, 1003-1008.	2.6	20
47	Family Discord is Associated with Increased Substance Use for Pregnant Substance Users. Substance Users user and Misuse, 2014, 49, 326-332.	1.4	20
48	Medication treatment for opioid use disorder in expectant mothers (MOMs): Design considerations for a pragmatic randomized trial comparing extended-release and daily buprenorphine formulations. Contemporary Clinical Trials, 2020, 93, 106014.	1.8	20
49	Motivation Enhancement Therapy with pregnant substance-abusing women: Does baseline motivation moderate efficacy?. Drug and Alcohol Dependence, 2009, 101, 74-79.	3.2	19
50	Cigarette Smoking During Substance Use Disorder Treatment: Secondary Outcomes from a National Drug Abuse Treatment Clinical Trials Network study. Journal of Substance Abuse Treatment, 2015, 53, 39-46.	2.8	19
51	Treating Nicotine Dependence by Targeting Attention-Deficit/ Hyperactivity Disorder (ADHD) With OROS Methylphenidate. Journal of Clinical Psychiatry, 2013, 74, 983-990.	2.2	19
52	Sex differences in disinhibition and its relationship to physical abuse in a sample of stimulant-dependent patients. Drug and Alcohol Dependence, 2013, 129, 158-162.	3.2	18
53	The potential impact of recruitment method on sample characteristics and treatment outcomes in a psychosocial trial for women with co-occurring substance use disorder and PTSD. Drug and Alcohol Dependence, 2012, 120, 225-228.	3.2	17
54	Association of methadone dose with substance use and treatment retention in pregnant and postpartum women with opioid use disorder. Journal of Substance Abuse Treatment, 2017, 80, 33-36.	2.8	17

#	Article	IF	CITATIONS
55	Baseline Cigarette Smoking Status as a Predictor of Virologic Suppression and CD4 Cell Count During One-Year Follow-Up in Substance Users with Uncontrolled HIV Infection. AIDS and Behavior, 2018, 22, 2026-2032.	2.7	17
56	Evaluation of buspirone for relapse-prevention in adults with cocaine dependence: An efficacy trial conducted in the real world. Contemporary Clinical Trials, 2012, 33, 993-1002.	1.8	16
57	Attention-deficit/hyperactivity disorder (ADHD) symptoms, craving to smoke, and tobacco withdrawal symptoms in adult smokers with ADHD. Drug and Alcohol Dependence, 2012, 124, 268-273.	3.2	16
58	Validation and threshold identification of a prescription drug monitoring program clinical opioid risk metric with the WHO alcohol, smoking, and substance involvement screening test. Drug and Alcohol Dependence, 2021, 228, 109067.	3.2	15
59	Design considerations for a study to evaluate the impact of smoking cessation treatment on stimulant use outcomes in stimulant-dependent individuals. Contemporary Clinical Trials, 2012, 33, 197-205.	1.8	14
60	Characteristics of Northern Plains American Indians Seeking Substance Abuse Treatment in an Urban, Non-Tribal Clinic: A Descriptive Study. Community Mental Health Journal, 2013, 49, 714-721.	2.0	14
61	A systematic approach to subgroup analyses in a smoking cessation trial. American Journal of Drug and Alcohol Abuse, 2015, 41, 498-507.	2.1	14
62	A brief telephone-delivered peer intervention to encourage enrollment in medication for opioid use disorder in individuals surviving an opioid overdose: Results from a randomized pilot trial. Drug and Alcohol Dependence, 2020, 216, 108270.	3.2	14
63	The association between regular cocaine use, with and without tobacco co-use, and adverse cardiovascular and respiratory outcomes. Drug and Alcohol Dependence, 2020, 214, 108136.	3.2	14
64	Prescription Drug Abuse as a Public Health Problem in Ohio: A Case Report. Public Health Nursing, 2012, 29, 553-562.	1.5	13
65	Preliminary evaluation of a model of stimulant use, oxidative damage and executive dysfunction. American Journal of Drug and Alcohol Abuse, 2013, 39, 227-234.	2.1	13
66	A tale of two stimulants: Mentholated cigarettes may play a role in cocaine, but not methamphetamine, dependence. Drug and Alcohol Dependence, 2013, 133, 845-851.	3.2	13
67	The association between cigarette smoking, virologic suppression, andÂCD4+Âlymphocyte count in HIV-Infected Russian women. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2017, 29, 1102-1106.	1.2	13
68	Metyrapone and cocaine: A double-blind, placebo-controlled drug interaction study. Pharmacology Biochemistry and Behavior, 2005, 80, 631-638.	2.9	12
69	The SRPHK1 outcome measure for cocaine-dependence trials combines self-report, urine benzoylecgonine levels, and the concordance between the two to determine a cocaine-use status for each study day. Drug and Alcohol Dependence, 2008, 93, 132-140.	3.2	12
70	Increasing Prenatal Care and Healthy Behaviors in Pregnant Substance Users. Journal of Psychoactive Drugs, 2010, 42, 73-81.	1.7	12
71	Pre-treatment change in a randomized trial with pregnant substance-abusing women in community-based outpatient treatment. Contemporary Clinical Trials, 2012, 33, 1074-1079.	1.8	12
72	The Effectiveness of Ultra-Low Magnitude Reinforcers: Findings From a "Real-World―Application of Contingency Management. Journal of Substance Abuse Treatment, 2017, 72, 111-116.	2.8	12

#	Article	IF	CITATIONS
73	Tobacco dependence counseling in a randomized multisite clinical trial. Contemporary Clinical Trials, 2012, 33, 576-582.	1.8	11
74	Design considerations for point-of-care clinical trials comparing methadone and buprenorphine treatment for opioid dependence in pregnancy and for neonatal abstinence syndrome. Contemporary Clinical Trials, 2014, 39, 158-165.	1.8	11
75	Blunts versus joints: Cannabis use characteristics and consequences among treatment-seeking adults. Drug and Alcohol Dependence, 2019, 198, 105-111.	3.2	11
76	Neonatal opioid withdrawal syndrome: a review of the science and a look toward the use of buprenorphine for affected infants. Journal of Perinatology, 2022, 42, 300-306.	2.0	11
77	HIV rapid testing in drug treatment: comparison across treatment modalities. Journal of Substance Abuse Treatment, 2013, 44, 369-374.	2.8	10
78	Optimal neurocognitive, personality and behavioral measures for assessing impulsivity in cocaine dependence. American Journal of Drug and Alcohol Abuse, 2014, 40, 455-462.	2.1	10
79	Toward personalized smoking-cessation treatment: Using a predictive modeling approach to guide decisions regarding stimulant medication treatment of attention-deficit/hyperactivity disorder (ADHD) in smokers. American Journal on Addictions, 2015, 24, 348-356.	1.4	10
80	Development and initial testing of a tailored telephone intervention delivered by peers to prevent recurring opioid-overdoses (TTIP-PRO). Health Education Research, 2016, 31, 146-160.	1.9	10
81	Efficacy of motivational enhancement therapy to decrease alcohol and illicit-drug use in pregnant substance users reporting baseline alcohol use. Journal of Substance Abuse Treatment, 2017, 77, 150-155.	2.8	10
82	Substance use outcomes in cocaine-dependent tobacco smokers: A mediation analysis exploring the role of sleep disturbance, craving, anxiety, and depression. Journal of Substance Abuse Treatment, 2019, 96, 53-57.	2.8	10
83	Evaluation of a personally-tailored opioid overdose prevention education and naloxone distribution intervention to promote harm reduction and treatment readiness in individuals actively using illicit opioids. Drug and Alcohol Dependence, 2020, 216, 108265.	3.2	10
84	An Exploration of Site Effects in a Multisite Trial of OROS-Methylphenidate for Smokers with Attention Deficit/Hyperactivity Disorder. American Journal of Drug and Alcohol Abuse, 2011, 37, 392-399.	2.1	9
85	Relationship of Age to Impulsivity and Decision Making: A Baseline Secondary Analysis of a Behavioral Treatment Study in Stimulant Use Disorders. Journal of Addictive Diseases, 2013, 32, 206-216.	1.3	9
86	Examination of the Hepatitis C Virus care continuum among individuals with an opioid use disorder in substance use treatment. Journal of Substance Abuse Treatment, 2017, 76, 77-80.	2.8	9
87	Therapist Effects in a NIDA CTN Intervention Trial with Pregnant Substance Abusing Women: Findings from a RCT with MET and TAU Conditions. Alcoholism Treatment Quarterly, 2012, 30, 224-237.	0.8	8
88	Risk of Methylphenidateâ€Induced Prehypertension in Normotensive Adult Smokers With Attention Deficit Hyperactivity Disorder. Journal of Clinical Hypertension, 2013, 15, 124-132.	2.0	8
89	Preliminary Evidence That Adherence to Counseling Mediates the Effects of Pretreatment Self-efficacy and Motivation on Outcome of a Cessation Attempt in Smokers with ADHD. Nicotine and Tobacco Research, 2013, 15, 393-400.	2.6	8
90	Neurocognitive Profiling of Adult Treatment Seekers Enrolled in a Clinical Trial of a Web-delivered Intervention for Substance Use Disorders. Journal of Addiction Medicine, 2018, 12, 99-106.	2.6	8

#	Article	IF	CITATIONS
91	Knowledge of and interest in opioid overdose education and naloxone distribution among US veterans on chronic opioids for addiction or pain. Drugs: Education, Prevention and Policy, 2016, 23, 322-327.	1.3	6
92	Blunt use and menthol cigarette smoking: An examination of adult marijuana users. Addictive Behaviors, 2020, 102, 106153.	3.0	6
93	The coupling of nicotine and stimulant craving during treatment for stimulant dependence Journal of Consulting and Clinical Psychology, 2016, 84, 230-237.	2.0	6
94	Anxiety and Depressed Mood Decline Following Smoking Abstinence in Adult Smokers with Attention Deficit Hyperactivity Disorder. Journal of Substance Abuse Treatment, 2015, 59, 104-108.	2.8	5
95	Design considerations for a pilot trial using a novel approach for evaluating smoking-cessation medication in methadone-maintained smokers. Contemporary Clinical Trials, 2016, 47, 334-339.	1.8	5
96	Evaluating Nicotine Craving, Withdrawal, and Substance Use as Mediators of Smoking Cessation in Cocaine- and Methamphetamine-Dependent Patients. Nicotine and Tobacco Research, 2016, 18, 1196-1201.	2.6	5
97	Design considerations for a remote randomized multi-site clinical trial evaluating an e-health self-management program for chronic pain patients receiving opioid therapy. Contemporary Clinical Trials, 2021, 101, 106245.	1.8	5
98	Psychosocial treatments for women with substance use disorders. Obstetrics and Gynecology Clinics of North America, 2003, 30, 483-499.	1.9	4
99	Introduction to Special Issue on Tobacco and Other Substance Use Disorders: Links and Implications. American Journal of Drug and Alcohol Abuse, 2017, 43, 129-131.	2.1	4
100	Cigarette smoking in pregnant substance users: Association with substance use and desire to quit. Journal of Addictive Diseases, 2017, 36, 88-91.	1.3	4
101	Improving Treatment for Opioid Dependence: A Perspective From the Ohio Valley Node of the NIDA Clinical Trials Network. Progress in Community Health Partnerships: Research, Education, and Action, 2014, 8, 99-107.	0.3	3
102	An Evaluation of Substance Abuse Treatment and HIV Education on Safe Sex Practices in Cocaine Dependent Individuals. ISRN Addiction, 2014, 2014, 1-7.	0.9	3
103	Exploring longitudinal course and treatment-baseline severity interactions in secondary outcomes of smoking cessation treatment in individuals with attention-deficit hyperactivity disorder. American Journal of Drug and Alcohol Abuse, 2018, 44, 653-659.	2.1	3
104	Differential Posttreatment Outcomes of Methylphenidate for Smoking Cessation for Individuals With ADHD. American Journal on Addictions, 2019, 28, 497-502.	1.4	3
105	Is it "loud―enough?: A qualitative investigation of blunt use among African American young adults. Journal of Ethnicity in Substance Abuse, 2020, , 1-15.	0.9	3
106	Reductions in tobacco use in naltrexone, relative to buprenorphine-maintained individuals with opioid use disorder: Secondary analysis from the National Drug Abuse Treatment Clinical Trials Network. Journal of Substance Abuse Treatment, 2021, 130, 108489.	2.8	3
107	Not getting lost in translational science: A tool for navigating the pre-implementation phase of multi-site pharmacological clinical trials. Applied Clinical Trials, 2014, 23, 36-39.	0.5	3
108	Validation of the tobacco, alcohol, prescription medication, and other substance use (TAPS) tool with the WHO alcohol, smoking, and substance Involvement screening test (ASSIST). Addictive Behaviors, 2022, 126, 107178.	3.0	3

#	Article	IF	CITATIONS
109	Osmotic Release Oral System Methylphenidate Prevents Weight Gain during a Smoking-Cessation Attempt in Adults with ADHD. Nicotine and Tobacco Research, 2013, 15, 583-587.	2.6	2
110	Increased Morbidity and Mortality in Hypertensive Patients With Substance Use Disorders: Electronic Health Record Findings. Journal of Studies on Alcohol and Drugs, 2020, 81, 471-478.	1.0	2
111	Pain Severity and Interference and Substance Use among Community Pharmacy Patients Prescribed Opioids: A Secondary Analysis of the PHARMSCREEN Study. Journal of Pain, 2022, , .	1.4	2
112	Predicting Treatment Response in Adolescents with ADHD Who Use Substances. The ADHD Report, 2013, 21, 1-5.	0.6	0
113	Pharmacodynamics Must Inform Statistics: An Example from a Cocaine Dependence Pharmacotherapy Trial. ISRN Addiction, 2014, 2014, 1-7.	0.9	0